April 2007
Volume 48, Issue 4
Free
Retina  |   April 2007
Scavenger Receptors for Oxidized Lipoprotein in Age-Related Macular Degeneration
Author Affiliations
  • Motohiro Kamei
    From the Department of Ophthalmology, Graduate School of Medicine, Osaka University, Suita, Japan; the
  • Kazuhito Yoneda
    Departments of Ophthalmology and
  • Noriaki Kume
    Department of Cardiovascular Medicine, Graduate School of Medicine, and the
  • Mihoko Suzuki
    From the Department of Ophthalmology, Graduate School of Medicine, Osaka University, Suita, Japan; the
  • Hiroyuki Itabe
    Department of Biological Chemistry, School of Pharmaceutical Science, Showa University, Tokyo, Japan; and the
  • Ken-ichi Matsuda
    Anatomy and Neurobiology, Kyoto Prefectural University of Medicine, Kyoto, Japan; the
  • Takeshi Shimaoka
    Molecular Preventive Medicine, Graduate School of Medicine, Tokyo University, Tokyo, Japan.
  • Manabu Minami
    Department of Cardiovascular Medicine, Graduate School of Medicine, and the
  • Shin Yonehara
    Graduate School of Biostudies, Kyoto University, Kyoto, Japan; the
  • Toru Kita
    Department of Cardiovascular Medicine, Graduate School of Medicine, and the
  • Shigeru Kinoshita
    Departments of Ophthalmology and
Investigative Ophthalmology & Visual Science April 2007, Vol.48, 1801-1807. doi:https://doi.org/10.1167/iovs.06-0699
  • Views
  • PDF
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Motohiro Kamei, Kazuhito Yoneda, Noriaki Kume, Mihoko Suzuki, Hiroyuki Itabe, Ken-ichi Matsuda, Takeshi Shimaoka, Manabu Minami, Shin Yonehara, Toru Kita, Shigeru Kinoshita; Scavenger Receptors for Oxidized Lipoprotein in Age-Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2007;48(4):1801-1807. https://doi.org/10.1167/iovs.06-0699.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

purpose. The accumulation of macrophages is known to be involved in the pathogenesis of age-related macular degeneration (AMD), but the reasons why macrophages accumulate in AMD lesions have not been determined. Because the histopathology of AMD has some factors common with those of atherosclerosis, the authors hypothesized that macrophages accumulate to take up oxidized lipoproteins in the eyes of patients with AMD, as has been demonstrated in atherosclerosis.

methods. Immunohistochemistry was performed on 10 surgically excised choroidal neovascular (CNV) membranes from eyes with AMD. An antibody against oxidized lipoprotein and antibodies against the scavenger receptors SR-PSOX and LOX-1 were used. Antibodies against cytokeratin, CD68, and von Willebrand factor were used to identify retinal pigment epithelium (RPE), macrophages, and vascular endothelial cells, respectively. RT-PCR was performed to detect the mRNAs of the scavenger receptors in the CNV membranes.

results. Oxidized lipoproteins were immunohistochemically detected in the CNV membranes. Intense immunostaining was observed at the surface of the CNV membranes with the SR-PSOX antibody, whereas LOX-1 immunostaining was weak. Cells expressing scavenger receptors were found to be predominantly macrophages with a minority of RPE. Both SR-PSOX and LOX-1 mRNAs were detected in CNV membranes.

conclusions. Oxidized lipoproteins are present in AMD lesions. Macrophages and RPE in the CNV membranes express cell surface scavenger receptors for oxidized lipoproteins. These findings suggest that macrophages may accumulate to take up oxidized lipoproteins in AMD and that the control of oxidative stress and macrophage responses may therefore be potential treatments for AMD.

Age-related macular degeneration (AMD) is a leading cause of legal blindness in the elderly in the United States 1 and Europe and is rapidly increasing in Asia. 2 Several types of treatments, including photodynamic therapy, 3 anti-VEGF therapy, 4 and macular translocation surgery, 5 6 have been recently developed to treat AMD. However, the pathogenesis of AMD has not been fully understood, 7 8 which results in limited options for current therapies. 
AMD is classified into two types: the dry type and the wet type. The wet type of AMD, which is characterized by formation of choroidal neovascular (CNV) membranes, affects 90% of patients with severe visual loss due to AMD. Earlier studies have demonstrated that macrophages accumulate in the tissues of eyes with the wet-type AMD, especially in the CNV membranes. 9 10 11 12 . They may play an important role by secreting cytokines and enzymes that induce and enhance neovascularization. 13 In keeping with this idea, the depletion of macrophages reduces CNV formation in an animal model. 14 15 Despite the suggestion that macrophages may play a crucial role in neovascular membrane formation in eyes with AMD, the reason that they accumulate in the AMD lesion remains unknown. 
In a histopathological study, Killingsworth et al. 16 observed that macrophages and phospholipid-containing debris were colocalized in Bruch’s membrane in eyes with AMD. Curcio et al. 17 also demonstrated an age-related accumulation of cholesterol esters in Bruch’s membrane similar to that observed in the arterial intima. These and other studies 18 19 suggest that the histopathology of AMD has some factors common with those of atherosclerosis. 
The cellular uptake of oxidized low-density lipoprotein by macrophages and vascular endothelial cells plays a crucial role in the pathogenesis of atherosclerosis. 20 Because the pathologic changes in AMD are similar to those in atherosclerosis 18 19 and atherosclerosis may contribute to the pathogenesis of AMD, 21 22 we hypothesized that macrophages accumulate to take up oxidized lipoproteins in the macular area of eyes with AMD as in the arterial intima in cases with atherosclerosis. To test this hypothesis, we investigated whether oxidized lipoproteins were present in the AMD lesions and whether oxidized lipoprotein-specific cell-surface receptors were expressed in AMD lesions. We also determined what types of cells express those scavenger receptors. 
Materials and Methods
Collection and Preparation of CNV Membranes
As a treatment for AMD, choroidal neovascular membranes were surgically excised from 13 eyes of 13 patients with AMD, ages 57 to 80 years (average, 73 years), as descried previously. 23 After an explanation of the purpose of the study, an informed consent was obtained from each patient to collect and study the excised tissues. The procedures used to collect and prepare the tissues conformed to the tenets of the Declaration of Helsinki. 
Ten of the specimens were used for immunohistochemistry and three for mRNA extraction. For immunohistochemistry, the surgically excised CNV membranes were placed in balanced saline solution in the operating room, kept at 4°C, and embedded in optimum cutting temperature (OCT) compound (Sakura Finetechnical Co, Ltd., Tokyo, Japan) within 2 hours after excision. Cryosections, 8 μm thick, were made for immunohistochemistry. For RT-PCR analysis, the CNV membranes were placed in liquid nitrogen in the operating room immediately after surgical excision and kept at −80°C until RNA extraction. 
Immunohistochemistry for Oxidized Lipoproteins
Indirect immunohistochemistry was performed on cryosections of surgically excised membranes with a monoclonal antibody (IgM) against oxidized lipoproteins, FOH1a/DLH3. The antibody was generated by immunizing a mouse against homogenates of human atheroma. It has been found to recognize oxidized phosphatidylcholine as an epitope and has been used for detecting oxidized lipoproteins in atherosclerotic lesions. 24 The avidin-biotin complex immunoperoxidase technique (Vector Laboratories Inc., Burlingame, CA) was used. In brief, after the sections were fixed in cold 4% formaldehyde, the endogenous peroxidase activity was blocked by NaIO4. The specimens were incubated with 0.3% BSA-PBS to block nonspecific immunoreaction and then with DLH3 at a dilution of 1:100, followed by incubation with a biotinylated horse anti-mouse IgM antibody. The sections were then incubated with streptavidin-biotin complex labeled with peroxidase. The immunoreactivity was made visible with 3-amino-9-ethylcarbazole (AEC; Vector Laboratories, Inc.). Sections incubated with nonimmune mouse IgM as a primary antibody served as negative controls. 
For further characterization of the positive cells, double staining was performed with DLH3 and anti-CD68 (Zymed, South San Francisco, CA) to detect the distribution of macrophages. After DLH3 staining, the specimens were incubated with anti-CD68 monoclonal antibody at a dilution of 1:100, followed by incubation with a biotinylated horse anti-mouse IgG antibody. The sections were then incubated with ABC-AP reagent (Vectastain; Vector Laboratories, Inc.). The second substrate-chromogen solution (Vector blue; Vector Laboratories, Inc.) was incubated on the slides for 1 to 5 minutes. 
Immunohistochemistry for Scavenger Receptors
To identify scavenger receptors and cells expressing these receptors in CNV membranes, double staining was performed with an anti-scavenger receptor antibody and a cell marker antibody. After fixation in cold 4% formaldehyde, the sections were incubated with the primary antibody mixtures including one of the anti-scavenger receptor antibodies and one of the cell markers. Antibodies against scavenger receptors included anti-LOX-1 (lectin-like Ox-LDL receptor-1) monoclonal antibody 19 (1:50 dilution) and anti-SR-PSOX (scavenger receptor that binds phosphatidylserine and oxidized lipoprotein) polyclonal antibody 25 (1:200 dilution). Cell marker monoclonal antibodies included CD68 (1:400 dilution; Zymed), pan cytokeratin (1:500 dilution; Sigma-Aldrich, St. Louis, MO), and von Willebrand factor (wVF; 1:1000 dilution; Dako Co., Glostrup, Denmark). In cases in which the primary antibody mixture contained both monoclonal antibodies (e.g., a mixture of anti-LOX-1 antibody and a cell marker), the primary antibodies were mixed with a labeling kit (Zenon; Invitrogen-Molecular Probes, Inc, Eugene, OR), according to the manufacturer’s instruction. The specimens were incubated with the mixture for 1 hour at room temperature and then incubated with secondary antibodies, Alexa Fluor 488-conjugated anti-mouse IgG antibody and Alexa Fluor 546-conjugated anti-rabbit IgG antibody (Invitrogen-Molecular Probes), for 1 hour at room temperature. The specimens were examined with a confocal microscope. For control sections, a mixture of nonimmunized mouse IgG and rabbit IgG was applied as the primary antibody. 
The intensity of the immunologic reaction was graded semiquantitatively according to a previous report. 26 The grades for the degree of staining were: none (−), mild (+, up to one third of cells stained), moderate (++, one third to two thirds of cells stained), or heavy (+++, two thirds to all cells stained). The degree of staining of the scavenger receptors was determined by comparing the relative number of positively stained cells to all cells in the section. For each cell marker, the degree of staining was determined by comparing the relative number of double-stained cells that appeared yellow to all cells positively stained with each scavenger receptor antibody. 
Reverse Transcription-Polymerase Chain Reaction
Total cellular RNA was extracted from three CNV membranes (RNeasy Mini Kit; Qiagen, Valencia, CA), and the extracted RNA was reverse transcribed with random primers (Toyobo, Osaka, Japan). The transcribed cDNA was used for polymerase chain reaction amplification with specific primers for LOX-1, SR-PSOX, and GAPDH. The two specific primers used to amplify LOX-1 were 5′-TGCTCTAGAGCACGGCAACAAGCA-3′, and 5′-GGGATCCCGGTGCTCTTAGGTTTGCC-3′; for SR-PSOX 5′-ACTCAGCCAGGCAATGGCAAC-3′, and 5′-GGTATTAGAGTCAGGTGCCAC-3′; and for GAPDH 5′-GGTGAAGGTCGGTGTGAACG-3′ and 5′-CAAAGTTGTCATGGATGACC-3′. PCR amplification was performed by 35 cycles of denaturation, annealing, and elongation with polymerase (TaqDNA; Toyobo). For positive control of each scavenger receptor, total cellular RNA was isolated from a cultured human monocyte cell line, THP-1. 25  
Results
Oxidized Lipoproteins in CNV Membranes
Surgically excised CNV membranes were immunopositive to a monoclonal antibody against oxidized lipoprotein (Fig. 1) . Although the surgically excised neovascular tissues contained no retinal components except for RPE cells and did not show the normal tissue structure, immunoreactivity to oxidized-lipoprotein was present mainly in and around the area of the autofluorescent pigment granules. Double staining revealed that immunostaining of oxidized lipoproteins colocalized with the CD68-positive cells as well as cells with pigment granules (Fig. 2) , which suggested that oxidized lipoproteins are present on macrophages and RPE cells. 
Scavenger Receptors for Oxidized Lipoproteins
SR-PSOX was detected in all CNV membranes. The peripheral regions of the CNV membranes were strongly immunopositive and the membrane stroma mildly immunopositive for SR-PSOX. The distribution of LOX-1 was similar to that of SR-PSOX, but the immunostaining was less intense and was observed in only 6 of 10 samples (Table 1) . These results suggest that SR-PSOX was more prominent than LOX-1 in CNV membranes of eyes with AMD. 
Cells Expressing Scavenger Receptors for Oxidized Lipoproteins
To identify the cells expressing the scavenger receptors in the CNV membranes, we performed double staining with the cell-marker antibodies CD68, pan cytokeratin, and vWF factor, which stain macrophages, RPE cells, and vascular endothelial cells, respectively. 
Merging the double-stained images composed of a section stained with an anti-scavenger receptor antibody and anti-CD68 antibody (Fig. 3)demonstrated that almost all the CD68-positive cells (i.e., macrophages) were SR-PSOX positive, and 60% to 70% of these cells were also LOX-1 positive. In contrast, most SR-PSOX-positive cells and many LOX-1-positive cells were identical with CD68-positive cells (Table 1) . These results indicate that most macrophages expressed both scavenger receptors, but predominantly SR-PSOX. Cells expressing these scavenger receptors were mainly macrophages, but CNV membranes had a minor population of LOX-1-positive cells other than macrophages. 
In the merged images composed of sections stained with an antiscavenger receptor antibody and anti-pan cytokeratin antibody (Fig. 4) , almost all pan-cytokeratin-positive cells (i.e., RPE cells) were SR-PSOX negative, and most were LOX-1 positive. In contrast, most SR-PSOX-positive cells were pan cytokeratin negative, and many LOX-1-positive cells were identical with pan cytokeratin-positive cells (Table 1) . These results indicate that almost all RPE cells expressed only LOX-1. Cells expressing SR-PSOX were not the RPE cells, and there were cells other than RPE cells that expressed LOX-1. 
Images composed of sections stained with an anti-scavenger receptor antibody and anti-vWF factor antibody demonstrated that almost all the vWF-positive cells (i.e., vascular endothelial cells), were not SR-PSOX-positive, that some of those cells were LOX-1 positive, and that most of the SR-PSOX-positive or LOX-1-positive cells were not vWF-positive (Fig. 5 ; Table 1 ). These results indicate that only a limited number of vascular endothelial cells expressed only LOX-1. 
Summarizing the double-staining results, cells expressing SR-PSOX were almost exclusively macrophages, and cells expressing LOX-1 were macrophages and RPE cells, with a minority of vascular endothelial cells. Macrophages are the main cell type expressing scavenger receptors for oxidized lipoproteins. 
mRNAs of Scavenger Receptors for Oxidized Lipoproteins Expressed in CNV Membrane
To determine whether the mRNAs of scavenger receptors are expressed in human CNV membranes, RT-PCR analyses were performed on total cellular RNA extracted from three surgically excised CNV membranes. The mRNAs of both SR-PSOX and LOX-1 were detected in human CNV membranes (Fig. 6)
Discussion
Because the histopathological changes in AMD are similar to those seen in atherosclerosis, 9 10 11 12 16 17 18 19 we suspected that scavenger receptors for oxidized lipoproteins might be present in AMD lesions. Our results demonstrated that oxidized lipoproteins and the scavenger receptors for oxidized lipoproteins are colocalized in the CNV membranes of AMD eyes. We had already found that oxidized lipoproteins in the macula increase with age in normal eyes and in AMD eyes, compared with age-matched normal eyes. 27 These findings support our hypothesis that pathogenesis of AMD has some similarities with the pathologic mechanisms of atherosclerosis in which macrophages accumulate to ingest the oxidized low-density lipoprotein by scavenger receptors specific for oxidized lipoproteins at the early stage. 
Oxidized lipoproteins were observed in and around the area of the autofluorescent pigment granules and colocalized with RPE cells and macrophages. This finding suggests that oxidized lipoproteins may accumulate in RPE cells and Bruch’s membrane, which is consistent with the accumulation of cholesterol esters or phospholipid-containing debris in Bruch’s membrane. 17 18 In addition, considering that the antioxidized lipoprotein antibody DLH3 detects foam cells, which take up Ox-LDL in early atherosclerotic lesions, 24 the positive staining may in part indicate oxidized lipoprotein-laden cells, which are possibly RPE cells and macrophages. 
Although previous studies demonstrated that macrophages accumulate in AMD lesions, 9 10 11 12 16 it is not known why macrophages accumulate in these areas. van der Schaft et al. 28 reported that immune reactions do not appear to be involved in attracting the macrophages in AMD, because distinct immune complexes have not been found in the basal laminar deposits or in drusen. In this study, we found accumulation of oxidized lipoproteins and macrophages that possessed scavenger receptors. Oxidized lipoproteins have been shown to cause inflammatory reactions resulting in the accumulation of macrophages 29 30 31 in many studies on atherosclerosis, and the histopathology of atherosclerosis is similar to that of AMD. Chang et al. reported that oxidized phosphatidylcholine binds to C-reactive protein, an opsonic molecule activating the classic complement pathway and Fc-γ receptor endocytosis of macrophages. 29 30 Complements have also been shown in atherosclerotic plaques together with oxidized lipoprotein, C-reactive proteins, and macrophages. 31 In recent genetic investigations, Hageman et al. 32 reported that a variation in the factor H gene increases the likelihood of development of AMD, and three other studies have demonstrated a linkage of the same gene to AMD. 33 34 35 These findings suggest that complement-macrophage reaction is involved in the accumulation of macrophage in AMD lesions. 
In our study, oxidized lipoproteins and macrophages were colocalized in AMD lesions and most macrophages in the CNV membranes expressed oxidized lipoprotein-specific scavenger receptors. Because the uptake of oxidized LDL by macrophages via scavenger receptors and accumulation of lipid-laden foam cells in the arterial intima are key events in early atherogenesis, 19 20 our findings suggest that macrophages may also accumulate in the area of the AMD, possibly to phagocytose oxidized lipoproteins through scavenger receptors. Furthermore, the expressions of SR-PSOX and LOX-1 are clinically important, because both of them have higher specificity to biologically degenerative LDL and not to artificially degenerative LDL, such as acetylated LDL than do other scavenger receptors. 19 25 36  
In atherosclerosis, the expressions of LOX-1 and SR-PSOX have specific sites. Endothelial cells expresses mainly LOX-1 from the early stage of atherosclerotic plaques, and macrophages and smooth muscle cells express LOX-1 in the advanced stage. 19 36 SR-PSOX is expressed mainly by macrophages, 25 although the relationship between the LOX-1-positive cells and the SR-PSOX-positive cells has not been determined. In this study, SR-PSOX were more prominent than LOX-1 in CNV membranes, cells expressing SR-PSOX were almost exclusively macrophages, and cells expressing LOX-1 were macrophages and RPE cells, with a minority of vascular endothelial cells. A specificity of scavenger receptors may also exist in AMD lesions, which means that SR-PSOX expressed on macrophages may function predominantly. We do not have any evidence of a relationship between the LOX-1-positive RPE and SR-PSOX-positive macrophages. 
In conclusion, our results provide new and significant information on the close link between oxidized lipoproteins and macrophages to AMD. Additional studies are needed to evaluate these changes more quantitatively and to clarify the results at the molecular level. Our findings support the suggestion that supplementation with antioxidants, vitamins, and minerals may reduce the risk of development of AMD. 37 Taken together with the results of recent studies demonstrating that macrophage depletion reduced CNV formation in an animal model, 14 15 our findings suggest that suppressing macrophage accumulation by controlling the macrophage responses to oxidative lipoproteins or suppressing phospholipid oxidation may be treatments for AMD. 
 
Figure 1.
 
Detection of oxidized lipoproteins in choroidal neovascular (CNV) membranes. Photomicrographs of sections from a CNV membrane that was incubated with a monoclonal antibody against oxidized lipoprotein (DLH3) (A) and nonimmune mouse IgM as a negative control (B). Immunostaining of oxidized lipoprotein (red) exists in and around the region of autofluorescent pigment granules in CNV membrane (arrows). Original magnification, ×20.
Figure 1.
 
Detection of oxidized lipoproteins in choroidal neovascular (CNV) membranes. Photomicrographs of sections from a CNV membrane that was incubated with a monoclonal antibody against oxidized lipoprotein (DLH3) (A) and nonimmune mouse IgM as a negative control (B). Immunostaining of oxidized lipoprotein (red) exists in and around the region of autofluorescent pigment granules in CNV membrane (arrows). Original magnification, ×20.
Figure 2.
 
Double staining of oxidized lipoproteins and CD68 in CNV membranes. Immunoreactions with the anti-oxidized lipoprotein antibody (red) are colocalized with those with anti-CD68 antibody (blue: arrowheads) as well as pigment granules (arrows). These results suggest that oxidized lipoproteins are present in macrophages and RPE cells. Bar, 10 μm. Original magnification, ×630.
Figure 2.
 
Double staining of oxidized lipoproteins and CD68 in CNV membranes. Immunoreactions with the anti-oxidized lipoprotein antibody (red) are colocalized with those with anti-CD68 antibody (blue: arrowheads) as well as pigment granules (arrows). These results suggest that oxidized lipoproteins are present in macrophages and RPE cells. Bar, 10 μm. Original magnification, ×630.
Table 1.
 
Immunohistochemical Staining for Scavenger Receptors and Rate of Cell Markers in CNV Associated with AMD
Table 1.
 
Immunohistochemical Staining for Scavenger Receptors and Rate of Cell Markers in CNV Associated with AMD
Case Age Gender SR-PSOX CD68 PCK vWF LOX-1 CD68 PCK vWF
1 65 F + +++ + +
2 77 F ++ ++ + ++ ++ +
3 70 M +++ +++ ++ ++ ++
4 72 F +++ +++ NA NA NA
5 65 M +++ +++ + ++ + ++ +
6 68 M +++ +++ NA NA NA
7 76 F + ++ + +
8 71 M +++ +++ NA NA NA
9 69 M ++ +++ NA NA NA
10 61 M +++ +++ + ++ +
Figure 3.
 
Localization of scavenger receptors and macrophages. Images composed of a section stained with anti-SR-PSOX polyclonal antibody (red) and another with anti-CD68 monoclonal antibody (green), and a merged image (A, B) demonstrates that almost all CD68-positive cells were SR-PSOX positive. Serial sections of the CNV membrane were stained with anti-LOX-1 monoclonal antibody (red) and anti-CD68 monoclonal antibody (green), and a merged image (C, D) demonstrates that 60% to 70% of the CD68-positive cells were LOX-1 positive. Most, but not all SR-PSOX- or LOX-1-positive cells were identical with CD68-positive cells. Magnification: (A) ×7; (B, D) ×126; (C) ×14.
Figure 3.
 
Localization of scavenger receptors and macrophages. Images composed of a section stained with anti-SR-PSOX polyclonal antibody (red) and another with anti-CD68 monoclonal antibody (green), and a merged image (A, B) demonstrates that almost all CD68-positive cells were SR-PSOX positive. Serial sections of the CNV membrane were stained with anti-LOX-1 monoclonal antibody (red) and anti-CD68 monoclonal antibody (green), and a merged image (C, D) demonstrates that 60% to 70% of the CD68-positive cells were LOX-1 positive. Most, but not all SR-PSOX- or LOX-1-positive cells were identical with CD68-positive cells. Magnification: (A) ×7; (B, D) ×126; (C) ×14.
Figure 4.
 
Localization of scavenger receptors and retinal pigment epithelium. Images composed of a section stained with anti-SR-PSOX polyclonal antibody (red) and anti-pan cytokeratin monoclonal antibody (green) and a merged image shows that almost all pan cytokeratin-positive cells were SR-PSOX negative. Serial sections of the CNV membrane stained with anti-LOX-1 monoclonal antibody (red) and anti-pan cytokeratin monoclonal antibody (green) and a merged image shows that almost all pan cytokeratin-positive cells were LOX-1 positive. Not all LOX-1-positive cells are identical with pan cytokeratin-positive cells. Magnification: (A, C) ×7; (B) ×20; (D) ×40.
Figure 4.
 
Localization of scavenger receptors and retinal pigment epithelium. Images composed of a section stained with anti-SR-PSOX polyclonal antibody (red) and anti-pan cytokeratin monoclonal antibody (green) and a merged image shows that almost all pan cytokeratin-positive cells were SR-PSOX negative. Serial sections of the CNV membrane stained with anti-LOX-1 monoclonal antibody (red) and anti-pan cytokeratin monoclonal antibody (green) and a merged image shows that almost all pan cytokeratin-positive cells were LOX-1 positive. Not all LOX-1-positive cells are identical with pan cytokeratin-positive cells. Magnification: (A, C) ×7; (B) ×20; (D) ×40.
Figure 5.
 
Localization of scavenger receptors and vascular endothelium. Images of a section stained with anti-SR-PSOX polyclonal antibody (red) and anti-vWF monoclonal antibody (green) and a merged image demonstrate that almost all the vWF positive cells were not SR-PSOX positive and that most of the SR-PSOX-positive cells were not vWF positive. Serial sections of the CNV membrane were stained with anti-LOX-1 monoclonal antibody (red) and anti-vWF monoclonal antibody (green), and a merged image demonstrates that some of the vWF-positive cells were LOX-1 positive and that most of LOX-1 positive cells were not vWF positive. Magnification: (A) ×14; (D) ×30.
Figure 5.
 
Localization of scavenger receptors and vascular endothelium. Images of a section stained with anti-SR-PSOX polyclonal antibody (red) and anti-vWF monoclonal antibody (green) and a merged image demonstrate that almost all the vWF positive cells were not SR-PSOX positive and that most of the SR-PSOX-positive cells were not vWF positive. Serial sections of the CNV membrane were stained with anti-LOX-1 monoclonal antibody (red) and anti-vWF monoclonal antibody (green), and a merged image demonstrates that some of the vWF-positive cells were LOX-1 positive and that most of LOX-1 positive cells were not vWF positive. Magnification: (A) ×14; (D) ×30.
Figure 6.
 
Scavenger receptor mRNA were present in CNV membranes. RT-PCR revealed expression of both SR-PSOX mRNA (lane 6) and LOX-1 mRNA (lane 7) in human CNV membranes. Lane 1: molecular marker; lanes 2 to 4: positive control; lanes 5 to 7: CNV membrane; lanes 2 and 5: GAPDH; lanes 3 and 6: SR-PSOX; lanes 4 and 7: LOX-1.
Figure 6.
 
Scavenger receptor mRNA were present in CNV membranes. RT-PCR revealed expression of both SR-PSOX mRNA (lane 6) and LOX-1 mRNA (lane 7) in human CNV membranes. Lane 1: molecular marker; lanes 2 to 4: positive control; lanes 5 to 7: CNV membrane; lanes 2 and 5: GAPDH; lanes 3 and 6: SR-PSOX; lanes 4 and 7: LOX-1.
FineSL, BergerJW, MaguireMG, HoAC. Age-related macular degeneration. N Engl J Med. 2000;342:483–492. [CrossRef] [PubMed]
MiyazakiM, KiyoharaY, YoshidaA, IidaM, NoseY, IshibashiT. The 5-year incidence and risk factors for age-related maculopathy in a general Japanese population: the Hisayama study. Invest Ophthalmol Vis Sci. 2005;46:1907–1910. [CrossRef] [PubMed]
Schmidt-ErfurthU, MillerJW, SickenbergM, et al. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study. Arch Ophthalmol. 1999;117:1177–1187. [CrossRef] [PubMed]
Eyetech Study Group. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina. 2002;22:143–152. [CrossRef] [PubMed]
MachemerR. Macular translocation. Am J Ophthalmol. 1998;125:698–700. [CrossRef] [PubMed]
KameiM, TanoY, YasuharaT, OhjiM, LewisH. Macular translocation with chorioscleral outfolding: 2-year results. Am J Ophthalmol. 2004;138:574–581. [CrossRef] [PubMed]
ZarbinMA. Age-related macular degeneration: review of pathogenesis. Eur J Ophthalmol. 1998;8:199–206. [PubMed]
KameiM, HollyfieldJG. TIMP-3 in Bruch’s membrane: changes during aging and in age-related macular degeneration. Invest Ophthalmol Vis Sci. 1999;40:2367–2375. [PubMed]
GrossniklausHE, CingleKA, YoonYD, KetkarN, L’HernaultN, BrownS. Correlation of histologic 2-dimensional reconstruction and confocal scanning laser microscopic imaging of choroidal neovascularization in eyes with age-related maculopathy. Arch Ophthalmol. 2000;118:625–629. [CrossRef] [PubMed]
LopezPF, GrossniklausHE, LambertHM, et al. Pathologic features of surgically excised subretinal neovascular membranes in age-related macular degeneration. Am J Ophthalmol. 1991;112:647–656. [CrossRef] [PubMed]
DastgheibK, GreenWR. Granulomatous reaction to Bruch’s membrane in age-related macular degeneration. Arch Ophthalmol. 1994;112:813–818. [CrossRef] [PubMed]
GrossniklausHE, MiskalaPH, GreenWR, et al. Histopathologic and ultrastructural features of surgically excised subfoveal choroidal neovascular lesions: submacular surgery trials report no. 7. Arch Ophthalmol. 2005;123:914–921. [CrossRef] [PubMed]
OhH, TakagiH, TakagiC, et al. The potential angiogenic role of macrophages in the formation of choroidal neovascular membranes. Invest Ophthalmol Vis Sci. 1999;40:1891–1898. [PubMed]
SakuraiE, AnandA, AmbatiBK, van RooijenN, AmbatiJ. Macrophage depletion inhibits experimental choroidal neovascularization. Invest Ophthalmol Vis Sci. 2003;44:3578–3585. [CrossRef] [PubMed]
Espinosa-HeidmannDG, SunerIJ, Marin-CastanoME, HernandezEP, Pereira-SimonS, CousinsSW. Macrophage depletion diminishes lesion size and severity in experimental choroidal neovascularization. Invest Ophthalmol Vis Sci. 2003;44:3586–3592. [CrossRef] [PubMed]
KillingsworthMC, SarksJP, SarksSH. Macrophages related to Bruch’s membrane in age-related macular degeneration. Eye. 1990;4:613–621. [CrossRef] [PubMed]
CurcioCA, MillicanCL, BaileyT, KruthHS. Accumulation of cholesterol with age in human Bruch’s membrane. Invest Ophthalmol Vis Sci. 2001;42:265–274. [PubMed]
MullinsRF, RussellSR, AndersonDH, HagemanGS. Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease. FASEB J. 2000;14:835–846. [PubMed]
KataokaH, KumeN, MiyamotoS, et al. Expression of lectinlike oxidized low-density lipoprotein receptor-1 in human atherosclerotic lesions. Circulation. 1999;99:3110–3117. [CrossRef] [PubMed]
WitztumJL, SteinbergD. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest. 1991;88:1785–1792. [CrossRef] [PubMed]
FriedmanE. The role of the atherosclerotic process in the pathogenesis of age-related macular degeneration. Am J Ophthalmol. 2000;130:658–663. [CrossRef] [PubMed]
VingerlingJR, DielemansI, BotsML, HofmanA, GrobbeeDE, de JongPT. Age-related macular degeneration is associated with atherosclerosis. The Rotterdam Study. Am J Epidemiol. 1995;142:404–409. [PubMed]
SawaM, KameiM, OhjiM, MotokuraM, SaitoY, TanoY. Changes in fluorescein angiogram early after surgical removal of choroidal neovascularization in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2002;240:12–16. [CrossRef] [PubMed]
ItabeH, TakeshimaE, IwasakiH, et al. A monoclonal antibody against oxidized lipoprotein recognizes foam cells in atherosclerotic lesions: complex formation of oxidized phosphatidylcholines and polypeptides. J Biol Chem. 1994;269:15274–15279. [PubMed]
ShimaokaT, KumeN, MinamiM, et al. Molecular cloning of a novel scavenger receptor for oxidized low density lipoprotein, SR-PSOX, on macrophages. J Biol Chem. 2000;275:40663–40666. [CrossRef] [PubMed]
GrossniklausHE, LingJX, WallaceTM, et al. Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization. Mol Vis. 2002;8:119–126. [PubMed]
SuzukiM, KameiM, ItabeH, et al. Oxidized phospholipids in the macula increased with age and in eyes with age-related macular degeneration. Mol Vis. .In press.
van der SchaftTL, MooyCM, de BruijnWC, de JongPT. Early stages of age-related macular degeneration: an immunofluorescence and electron microscopy study. Br J Ophthalmol. 1993;77:657–661. [CrossRef] [PubMed]
ChangMK, BinderCJ, TorzewskiM, WitztumJL. C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci USA. 2002;99:13043–13048. [CrossRef] [PubMed]
HazenSL, ChisolmGM. Oxidized phosphatidylcholines: pattern recognition ligands for multiple pathways of the innate immune response. Proc Natl Acad Sci USA. 2002;99:12515–12517. [CrossRef] [PubMed]
MeuwissenM, van der WalAC, NiessenHW, et al. Colocalisation of intraplaque C reactive protein, complement, oxidised low density lipoprotein, and macrophages in stable and unstable angina and acute myocardial infarction. J Clin Pathol. 2006;59:196–201. [CrossRef] [PubMed]
HagemanGS, AndersonDH, JohnsonLV, et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci USA. 2005;102:7227–7232. [CrossRef] [PubMed]
KleinRJ, ZeissC, ChewEY, et al. Complement factor H polymorphism in age-related macular degeneration. Science. 2005;308:385–389. [CrossRef] [PubMed]
HainesJL, HauserMA, SchmidtS, et al. Complement factor H variant increases the risk of age-related macular degeneration. Science. 2005;308:419–421. [CrossRef] [PubMed]
EdwardsAO, RitterR, III, AbelKJ, ManningA, PanhuysenC, FarrerLA. Complement factor H polymorphism and age-related macular degeneration. Science. 2005;308:421–424. [CrossRef] [PubMed]
MoriwakiH, KumeN, SawamuraT, et al. Ligand specificity of LOX-1, a novel endothelial receptor for oxidized low density lipoprotein. Arterioscler Thromb Vasc Biol. 1998;18:1541–1547. [CrossRef] [PubMed]
BresslerNM, BresslerSB, CongdonNG, et al. Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11. Arch Ophthalmol. 2003;121:1621–1624. [CrossRef] [PubMed]
Figure 1.
 
Detection of oxidized lipoproteins in choroidal neovascular (CNV) membranes. Photomicrographs of sections from a CNV membrane that was incubated with a monoclonal antibody against oxidized lipoprotein (DLH3) (A) and nonimmune mouse IgM as a negative control (B). Immunostaining of oxidized lipoprotein (red) exists in and around the region of autofluorescent pigment granules in CNV membrane (arrows). Original magnification, ×20.
Figure 1.
 
Detection of oxidized lipoproteins in choroidal neovascular (CNV) membranes. Photomicrographs of sections from a CNV membrane that was incubated with a monoclonal antibody against oxidized lipoprotein (DLH3) (A) and nonimmune mouse IgM as a negative control (B). Immunostaining of oxidized lipoprotein (red) exists in and around the region of autofluorescent pigment granules in CNV membrane (arrows). Original magnification, ×20.
Figure 2.
 
Double staining of oxidized lipoproteins and CD68 in CNV membranes. Immunoreactions with the anti-oxidized lipoprotein antibody (red) are colocalized with those with anti-CD68 antibody (blue: arrowheads) as well as pigment granules (arrows). These results suggest that oxidized lipoproteins are present in macrophages and RPE cells. Bar, 10 μm. Original magnification, ×630.
Figure 2.
 
Double staining of oxidized lipoproteins and CD68 in CNV membranes. Immunoreactions with the anti-oxidized lipoprotein antibody (red) are colocalized with those with anti-CD68 antibody (blue: arrowheads) as well as pigment granules (arrows). These results suggest that oxidized lipoproteins are present in macrophages and RPE cells. Bar, 10 μm. Original magnification, ×630.
Figure 3.
 
Localization of scavenger receptors and macrophages. Images composed of a section stained with anti-SR-PSOX polyclonal antibody (red) and another with anti-CD68 monoclonal antibody (green), and a merged image (A, B) demonstrates that almost all CD68-positive cells were SR-PSOX positive. Serial sections of the CNV membrane were stained with anti-LOX-1 monoclonal antibody (red) and anti-CD68 monoclonal antibody (green), and a merged image (C, D) demonstrates that 60% to 70% of the CD68-positive cells were LOX-1 positive. Most, but not all SR-PSOX- or LOX-1-positive cells were identical with CD68-positive cells. Magnification: (A) ×7; (B, D) ×126; (C) ×14.
Figure 3.
 
Localization of scavenger receptors and macrophages. Images composed of a section stained with anti-SR-PSOX polyclonal antibody (red) and another with anti-CD68 monoclonal antibody (green), and a merged image (A, B) demonstrates that almost all CD68-positive cells were SR-PSOX positive. Serial sections of the CNV membrane were stained with anti-LOX-1 monoclonal antibody (red) and anti-CD68 monoclonal antibody (green), and a merged image (C, D) demonstrates that 60% to 70% of the CD68-positive cells were LOX-1 positive. Most, but not all SR-PSOX- or LOX-1-positive cells were identical with CD68-positive cells. Magnification: (A) ×7; (B, D) ×126; (C) ×14.
Figure 4.
 
Localization of scavenger receptors and retinal pigment epithelium. Images composed of a section stained with anti-SR-PSOX polyclonal antibody (red) and anti-pan cytokeratin monoclonal antibody (green) and a merged image shows that almost all pan cytokeratin-positive cells were SR-PSOX negative. Serial sections of the CNV membrane stained with anti-LOX-1 monoclonal antibody (red) and anti-pan cytokeratin monoclonal antibody (green) and a merged image shows that almost all pan cytokeratin-positive cells were LOX-1 positive. Not all LOX-1-positive cells are identical with pan cytokeratin-positive cells. Magnification: (A, C) ×7; (B) ×20; (D) ×40.
Figure 4.
 
Localization of scavenger receptors and retinal pigment epithelium. Images composed of a section stained with anti-SR-PSOX polyclonal antibody (red) and anti-pan cytokeratin monoclonal antibody (green) and a merged image shows that almost all pan cytokeratin-positive cells were SR-PSOX negative. Serial sections of the CNV membrane stained with anti-LOX-1 monoclonal antibody (red) and anti-pan cytokeratin monoclonal antibody (green) and a merged image shows that almost all pan cytokeratin-positive cells were LOX-1 positive. Not all LOX-1-positive cells are identical with pan cytokeratin-positive cells. Magnification: (A, C) ×7; (B) ×20; (D) ×40.
Figure 5.
 
Localization of scavenger receptors and vascular endothelium. Images of a section stained with anti-SR-PSOX polyclonal antibody (red) and anti-vWF monoclonal antibody (green) and a merged image demonstrate that almost all the vWF positive cells were not SR-PSOX positive and that most of the SR-PSOX-positive cells were not vWF positive. Serial sections of the CNV membrane were stained with anti-LOX-1 monoclonal antibody (red) and anti-vWF monoclonal antibody (green), and a merged image demonstrates that some of the vWF-positive cells were LOX-1 positive and that most of LOX-1 positive cells were not vWF positive. Magnification: (A) ×14; (D) ×30.
Figure 5.
 
Localization of scavenger receptors and vascular endothelium. Images of a section stained with anti-SR-PSOX polyclonal antibody (red) and anti-vWF monoclonal antibody (green) and a merged image demonstrate that almost all the vWF positive cells were not SR-PSOX positive and that most of the SR-PSOX-positive cells were not vWF positive. Serial sections of the CNV membrane were stained with anti-LOX-1 monoclonal antibody (red) and anti-vWF monoclonal antibody (green), and a merged image demonstrates that some of the vWF-positive cells were LOX-1 positive and that most of LOX-1 positive cells were not vWF positive. Magnification: (A) ×14; (D) ×30.
Figure 6.
 
Scavenger receptor mRNA were present in CNV membranes. RT-PCR revealed expression of both SR-PSOX mRNA (lane 6) and LOX-1 mRNA (lane 7) in human CNV membranes. Lane 1: molecular marker; lanes 2 to 4: positive control; lanes 5 to 7: CNV membrane; lanes 2 and 5: GAPDH; lanes 3 and 6: SR-PSOX; lanes 4 and 7: LOX-1.
Figure 6.
 
Scavenger receptor mRNA were present in CNV membranes. RT-PCR revealed expression of both SR-PSOX mRNA (lane 6) and LOX-1 mRNA (lane 7) in human CNV membranes. Lane 1: molecular marker; lanes 2 to 4: positive control; lanes 5 to 7: CNV membrane; lanes 2 and 5: GAPDH; lanes 3 and 6: SR-PSOX; lanes 4 and 7: LOX-1.
Table 1.
 
Immunohistochemical Staining for Scavenger Receptors and Rate of Cell Markers in CNV Associated with AMD
Table 1.
 
Immunohistochemical Staining for Scavenger Receptors and Rate of Cell Markers in CNV Associated with AMD
Case Age Gender SR-PSOX CD68 PCK vWF LOX-1 CD68 PCK vWF
1 65 F + +++ + +
2 77 F ++ ++ + ++ ++ +
3 70 M +++ +++ ++ ++ ++
4 72 F +++ +++ NA NA NA
5 65 M +++ +++ + ++ + ++ +
6 68 M +++ +++ NA NA NA
7 76 F + ++ + +
8 71 M +++ +++ NA NA NA
9 69 M ++ +++ NA NA NA
10 61 M +++ +++ + ++ +
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×